|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 153.70 BDT | -0.77% |
|
+5.78% | +50.54% |
| 06-26 | Beximco suspension lifted; M1 payment date extension | AN |
| 06-24 | Beximco Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 | CI |
| Market Cap | 68.57B 557M 487M 449M 415M 787M 53.1B 800M 5.37B 2.11B 26.16B 2.09B 2.05B 89.93B | P/E 2026 * |
9.92x | P/E 2027 * | 7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 68.57B 557M 487M 449M 415M 787M 53.1B 800M 5.37B 2.11B 26.16B 2.09B 2.05B 89.93B | EV / Sales 2026 * |
1.25x | EV / Sales 2027 * | 1.13x |
| Free-Float |
85.91% | Yield 2026 * |
3.9% | Yield 2027 * | 5.53% |
| 1 day | -0.77% | ||
| 1 week | +5.78% | ||
| Current month | +9.32% | ||
| 1 month | +22.76% | ||
| 3 months | +30.92% | ||
| 6 months | +46.38% | ||
| Current year | +50.54% |
| 1 week | 149 |  | 158.5 |
| 1 month | 124.6 | | 158.5 |
| Current year | 99.5 | | 158.5 |
| 1 year | 90.4 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 255.4 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 2024-03-03 |
| Director of Finance/CFO | 63 | 2002-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2009-06-18 | |
| Director/Board Member | - | 2010-01-31 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 1984-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.77% | +5.78% | +60.77% | +5.13% | 557M | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,060B | |
| -0.82% | -2.30% | +63.79% | +62.00% | 619B | |
| -0.73% | -4.98% | +28.91% | +82.99% | 438B | |
| +0.33% | -1.17% | +31.07% | +27.09% | 333B | |
| -0.02% | -2.85% | +29.15% | +45.24% | 282B | |
| -3.89% | -11.22% | +22.81% | +27.30% | 267B | |
| +0.66% | -1.42% | -26.59% | -37.71% | 218B | |
| -0.06% | -2.88% | +23.07% | +62.33% | 196B | |
| -3.72% | -1.10% | +18.41% | +70.56% | 161B | |
| Average | -1.14% | -2.72% | +30.13% | +51.54% | 357.45B | |
| Weighted average by Cap. | -1.31% | -2.96% | +36.75% | +83.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.69B 444M 388M 358M 331M 628M 42.35B 638M 4.28B 1.68B 20.86B 1.67B 1.63B 71.73B | 60.64B 492M 431M 397M 367M 696M 46.96B 708M 4.75B 1.86B 23.13B 1.85B 1.81B 79.53B |
| Net income | 6.91B 56.08M 49.05M 45.24M 41.79M 79.29M 5.35B 80.62M 541M 212M 2.63B 211M 206M 9.06B | 9.13B 74.13M 64.84M 59.81M 55.24M 105M 7.07B 107M 715M 281M 3.48B 278M 272M 11.97B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-09 | BDT 153.70 | -0.77% | 1,309,421 |
| 26-07-08 | BDT 154.90 | -0.06% | 1,178,657 |
| 26-07-07 | BDT 155.00 | +3.33% | 3,279,516 |
| 26-07-06 | BDT 150.00 | -0.40% | 1,662,968 |
| 26-07-05 | BDT 150.60 | +3.65% | 2,752,963 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
